Friday, July 27, 2007 11:34:07 PM
Will Viread work better in monotherapy than Tyzeka... that is undetermined
All indications are GILD will promote Viread if / when approved.
Viread is a Nt
the approved Ns competitors - Baraclude and Tyzeka (telbivudine)
keep in mind telbivudine is the new kid on the block... as more clinical data becomes available... the picture will become clearer for telbivudine... Idenix is doing a head to head trials vs both Viread and Baraclude
The creation of a thousand forests is in one acorn.
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
